clinical trial · NCT04445831
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
Alzheimer's DiseaseCognitive ImpairmentTauopathiesMild Cognitive ImpairmentDementiaBrain DiseasesCentral Nervous System DiseasesACI-35.030ACI-35.030ACI-35.030PlaceboJACI-35.054JACI-35.054
brief summary
This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with early Alzheimer's Disease.
started
Jul 31, 2019
primary completion
Sep 5, 2023
completion
Sep 5, 2023
last updated
Feb 14, 2025
official title
A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol